Trial · NCT05348148
Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis
NCT05348148, Not applicable, Recruiting, Camillians Saint Mary's Hospital Luodong
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis. Trials, record NCT05348148. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05348148
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis
- NCT number
- NCT05348148
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 450 participants, estimated
- Lead sponsor
- Camillians Saint Mary's Hospital Luodong
- Conditions
- Allergic Rhinitis, Vasomotor Rhinitis
- Interventions
- Oral Levocetirizine, Combined Intranasal Mometasone Furoate with oral Levocetirizine, Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline
- First posted
- 2022-04-27
- Last updated
- 2022-04-27
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | alleviating darkness of shiners | Change from baseline darkness of shiners at 1 week after treatment. | Change from baseline of the darkness of shiners at 1 week after treatment. |
| Primary | alleviating darkness of shiners | Change from baseline darkness of shiners at 2 weeks after treatment. | Change from baseline of the darkness of shiners at 2 week after treatment. |
| Primary | alleviating darkness of shiners | Change from baseline darkness of shiners at 4 weeks after treatment. | Change from baseline of the darkness of shiners at 4 week after treatment. |
| Primary | alleviating area value of shiners | Change from baseline area value of shiners at 1 week after treatment. | Change from baseline of the area value of shiners at 1 week after treatment. |
| Primary | alleviating area value of shiners | Change from baseline area value of shiners at 2 week after treatment. | Change from baseline of the area value of shiners at 2 week after treatment. |
| Primary | alleviating area value of shiners | Change from baseline area value of shiners at 4 week after treatment. | Change from baseline of the area value of shiners at 4 week after treatment. |
| Secondary | alleviating darkness of shiners among groups | Change from baseline darkness of shiners at 1 week after treatment. | Change from baseline of the darkness of shiners at 1 week after treatment among groups (including oral Levocetirizine group, combined Intranasal Mometasone Furoate with oral Levocetirizine group, and combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group). |
| Secondary | alleviating darkness of shiners among groups | Change from baseline darkness of shiners at 2 week after treatment. | Change from baseline of the darkness of shiners at 2 week after treatment among groups (including oral Levocetirizine group, combined Intranasal Mometasone Furoate with oral Levocetirizine group, and combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group). |
| Secondary | alleviating darkness of shiners among groups | Change from baseline darkness of shiners at 4 week after treatment. | Change from baseline of the darkness of shiners at 4 week after treatment among groups (including oral Levocetirizine group, combined Intranasal Mometasone Furoate with oral Levocetirizine group, and combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group). |
| Secondary | alleviating area value of shiners among groups | Change from baseline area value of shiners at 1 week after treatment. | Change from baseline of the area value of shiners at 1 week after treatment among groups (including oral Levocetirizine group, combined Intranasal Mometasone Furoate with oral Levocetirizine group, and combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group). |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers23
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05348148
GET https://conductscience.org/api/trials/v1/NCT05348148/papers?page=2